Virbac: a report appreciated Stock

The action Virbac (PA:VIRB) stands out this Thursday on the Paris stock Exchange…

It asserts, in effect, a 5.2% shortly after 14h, the second highest increase in the DTH.

Investors welcome the decision of the animal health specialist, by agreement with the other shareholders, to defer for 3 years the option to purchase the balance of the chilean group Centrovet, where it currently holds 51% of the share capital.

This report is made on the same terms and price Virbac did not want to exercise the option at the end of the year so as not to weigh on its debt.

Wisdom also appreciated by Oddo, who in a note released this morning raised its council on Virbac from ‘neutral’ to ‘buy’ and increased its target price to 146 euros, against 126 euros previously.

If the problems and uncertainties are not all of the surveys, the intermediary is asked whether the low point is not now past and expects a gradual improvement in the newsflow, with the gradual recovery of Virbac in the United States.

Copyright (c) 2017 CercleFinance.com. All rights reserved.